The coronavirus pandemic has rocked the pharmaceutical and medical device communities, forcing the industry to confront the profound consequences that worldwide public health emergencies have on supply chains, pricing, clinical trial design, product launches, acquisitions and productivity in the workplace.
Center stage in the COVID-19 conversation is the search for vaccines. At the time of this writing, there are 130 vaccine candidates in pre-clinical development, seven in early-stage clinical trials and only one compound in pivotal Phase 3 human trials.
Clients have engaged The Evanston Group to provide teams of experienced clinical research consultants to help move compounds through late-stage human trials. As the world is watching and waiting for results, The Evanston Group’s mission-critical life science consulting services and game-changing healthcare innovations are at the forefront of the development process.
Coronavirus vaccines are expected to hit the market as soon as next year. Vaccines and new antiviral therapeutics are the most anticipated lines of defense to stop the human tragedy and reverse the pandemic’s effect on the global economy; until then, uncertainty about the virus will complicate pharmaceutical development and the industry landscape at large.
The Evanston Group’s vast network of high-caliber consultants has worked for the world’s most influential life science companies. Their expertise across a wide range of areas delivers value to partners like you who face urgent challenges. Our years of working on the most important projects for industry leaders make us uniquely qualified to advise you.
COVID-19 has disrupted supply chains, for example, placing pressure on commodity products like generics and biosimilars. Also, the accelerated industry trend toward tele-medicine engagement forces companies to adapt sales and marketing strategies to stay competitive. Moreover, clinical trials for non-COVID-19 candidates may be put on hold or require amendment of protocols to account for patient enrollment challenges. Investigators may need to discuss the expected results from clinical trials under way, the risks and potential changes in procedures.
COVID-19’s lockdowns and social distancing requirements are changing the traditional foundations of success in business, which revolve around relationships. The coronavirus pandemic is disconnecting communities; consequently, it’s an extraordinary opportunity for life science leaders to consider where current talents fit into their organization and whether a gap exists between the talent pool and the ability to swiftly meet stated priorities.
You can depend on The Evanston Group to help you implement program and project management, research and development, and technology projects with decisive results that guide you on a trajectory toward success. We are trusted advisors dedicated to clear, open and honest communication that comes from the experience and expertise to see around corners, and to anticipate next steps that move businesses forward.
The Evanston Group’s ability to match consultants with pharmaceutical and medical device companies yields results and a new way of thinking that takes programs and project management to new levels of success. In two decades, the company has grown strong relationships with senior executives and leaders at the most influential names in modern health care.
